

Cover Story
Clinical
Proven curative regimens containing platinum-based drugs—cisplatin and carboplatin—have become largely unavailable because of a nationwide drug shortage. The institutions that have some supplies of cisplatin and carboplatin are setting up algorithms for rationing their dwindling stocks, which usually means giving top priority to patients treated with curative intent and denying standard-of-care treatment to patients who cannot be cured but who can still benefit from these drugs.
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- With five-year cancer survival at an all-time high, does this mean people are living longer?
- House passes three-year extension of ACA subsidies with bipartisan support
- When “safe and effective” is not “reasonable and necessary”
We can curb excessive drug dosing and improve the quality of cancer care - Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- The Mark Foundation names 2026 Emerging Leader Award recipients
- A radiation oncologist’s perspective: Why we need to accelerate early detection strategies for lung cancers
















